LINDA LIN: Open Payments
NPI 1598349029 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,025 in 78 payments from 15 companies in 2025. Trend: 2023 $1,109 · 2024 $1,906 · 2025 $3,025
Food & beverage: $3,017Education: $8
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $572 |
| Axsome Therapeutics, Inc. | 9 | $476 |
| Otsuka America Pharmaceutical, Inc. | 12 | $444 |
| Neurocrine BioSciences, Inc. | 4 | $317 |
| Vanda Pharmaceuticals Inc. | 10 | $293 |
| Alkermes, Inc. | 8 | $281 |
| Lundbeck LLC | 9 | $182 |
| ACADIA Pharmaceuticals Inc | 2 | $128 |
| Teva Pharmaceuticals USA, Inc. | 1 | $106 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $78 |
Products named: REXULTI, COBENFY, Auvelity, INGREZZA, FANAPT, LYBALVI, NUPLAZID, UZEDY.
Industry payments across NY — which companies pay providers there.
